Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Professor of Medicine
Medical Director, Viral Hepatitis Center
Divisions of Infectious Diseases and Gastroenterology/Hepatology
Johns Hopkins University School of Medicine
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospiatl
Associate Clinical Professor
Division of Infectious Diseases
Department of Medicine
UC San Diego School of Medicine
La Jolla, California
Assistant Medical Director
Division of Research/Special Populations
Family Health Centers of San Diego
San Diego, California
Associate Professor of Medicine
Department of Internal Medicine
Addiction Medicine Fellowship
Yale School of Medicine
New Haven, Connecticut
Senior Scientific Director
Director, Scientific Services
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
The PIM planners and managers have nothing to disclose.
The ASAM planners and managers have nothing to disclose.
The INHSU planners and managers have nothing to disclose.
The HealthHCV planners and managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers involved in the screening, diagnosis, and treatment of patients infected with or at elevated risk of HCV.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, American Society of Addiction Medicine, International Network for Hepatitis in Substance Users and HealthHCV. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.7 contact hours.
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour (0.175 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-0000-19-620-H01-P.
Type of Activity: Knowledge
Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 02, 2019, through April 01, 2020:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Expert commentary on the importance of improving HCV treatment uptake in persons who inject drugs and effective linkage-to-care strategies
Clinical Care Options’ expert audio from Matthew J. Akiyama, MD, MSc, on challenges and opportunities for reducing HCV in correctional facilities
Downloadable slides from Clinical Care Options providing expert insights on HCV identification and care in correctional settings
Expert commentary from Christopher Byrne and Dr. John Dillon on evaluating an HCV treatment as prevention (TasP) model for PWID in Tayside, Scotland
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.